Bone Marrow Transplantation News

President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI.

Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.

NEW ORLEANS — Peter Chin-Hong, MD, Infectious Disease News Editorial Board member and professor of medicine at the University of California, San Francisco, School of Medicine, talks about emerging issues in solid organ transplantation, the focus of a session at ASM Microbe.

NEW ORLEANS — A novel, next-generation sequencing plasma assay identified a broad range of infections more quickly than conventional tests in stem cell transplant patients, researchers said.

NEW ORLEANS — Genovefa Papanicolaou, MD, an infectious disease specialist affiliated with Memorial Sloan Kettering Cancer Center in New York, discusses the significant problem of cytomegalovirus, or CMV, in hematopoietic cell transplantation patients.

CHICAGO — ASCO’s big-data initiative CancerLinQ announced a long-term partnership with the FDA to use patient data to evaluate the real-world use of newly approved cancer therapies, according to a press release.

National Cancer Survivors Day, recognized annually on the first Sunday in June, provides free education and networking to hospitals, support groups and other cancer-related organizations to help improve the quality of life of cancer survivors.

Seattle Children’s Research Institute has opened the first precision medicine clinical trial, which applies novel T-cell receptor sequencing and single-cell gene expression analysis, to help treat the immune system of pediatric IBD and bone marrow transplant patients, according to a press release.

Michael A. Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center, took over this spring as president of American Association for Cancer Research.

A reduced-intensity conditioning regimen yielded comparable RFS and OS as standard myeloablative conditioning among patients with myelodysplastic syndrome, according to results of the phase 3 RICMAC clinical trial.